New players have been added to the field of electric field therapy for tumors. AstraZeneca and Haier have jointly explored new treatment options for gastrointestinal tumors
无由窗置
发表于 2024-9-6 20:24:31
1166
0
0
On September 5th, AstraZeneca and Jiangsu Hailai Xinchuang Medical Technology Co., Ltd. (hereinafter referred to as Hailai Xinchuang) officially signed a clinical research cooperation agreement. According to the agreement, both parties will jointly carry out clinical research on the application of AstraZeneca immune checkpoint inhibitors combined with Hailey Xinchuang electric field therapy in solid tumors such as gastrointestinal tumors represented by biliary malignancies.
Tumor Treating Fields (TTF) is an innovative physical therapy modality for tumors. Previously, as a pioneer in tumor electric field therapy, Novocure's product Optune was currently the only globally approved product for market launch. In July 2020, Optune was introduced to the domestic market through Zaiding Medical. That year, Zaiding Medical's market value doubled, and Optune became the company's second largest pipeline, with a net revenue growth of 300%. Afterwards, Optune continued to grow at an annual rate of around 10%.
The tumor treatment electric field is currently in the import stage in China. Apart from Optune, which has been approved for the treatment of glioblastoma in China, there are no domestically produced products on the market yet. However, companies in China, including Jiangsu Hailai Xinchuang, Hunan Antaikang, and Zhejiang Saifukaier, are laying out in this emerging field.
Among them, the tumor electric field therapy device EFE-G100 independently developed by Hailai Xinchuang has been recognized as an innovative medical device by the National Medical Products Administration and is currently conducting multi center clinical trials. Hailai Xinchuang has also become the first TTF research and development enterprise in China and the second in the world to enter the multi center clinical stage.
From now on, the collaboration between AstraZeneca and Haier Innovation not only expands the application of electric field therapy in a wider range of tumor fields, but also sets a new paradigm for clinical research on drug combination innovative tumor treatment devices.
It is reported that, in addition to this cooperation, AstraZeneca will promote the clinical research of combined treatment of third-generation EGFR-TKI ohitinib, targeted HER2 ADC dtriazumab (developed in cooperation with the First Three Communist Party of China), immunocheckpoint inhibitors (including Tremelimumab and Duvalizumab), and the new BTK inhibitor achotinib, covering gastrointestinal tumors, lung cancer, breast cancer, blood tumors and other fields. As of now, more than 20 local pharmaceutical companies have applied and reached cooperation agreements with five Chinese local enterprises, including Shiyao Group and Yasheng Pharmaceutical, for joint treatment clinical research.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
-
据媒体报道,OpenAI正准备推出一款代号为“Operator”的全新AI助理产品,可以自动执行各种复杂操作,包括编写代码、预订旅行、自动电商购物等。根据内部员工爆料,OpenAI领导层预计将在2025年1月发布该产品,首 ...
- 永远的希望
- 昨天 11:06
- 支持
- 反对
- 回复
- 收藏
-
【小摩辣评“特朗普2.0”:关税大棒料打击经济、重燃通胀!】摩根大通资产管理公司(JPMorgan Asset Management)首席全球市场策略师David Kelly周三表示,当选总统特朗普激进的关税计划,可能会减缓全球经济,并给 ...
- besharp
- 昨天 12:37
- 支持
- 反对
- 回复
- 收藏
-
本报讯 (记者李豪悦)11月12日,腾讯音乐娱乐集团(以下简称“腾讯音乐”)宣布其截至2024年9月30日止第三季度的未经审计财务业绩。 2024年第三季度,腾讯音乐娱乐集团业绩表现稳健,总收入为70.2亿元,同 ...
- 覃志辉
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
新华财经上海11月13日电芯片制造商英伟达和软银集团的电信部门软银公司周三表示,两家公司已经试运行了全球首个人工智能和5G电信网络。 两家公司表示,该网络可以同时运行人工智能和5G工作负载,这一过程被 ...
- 惡魔獵人
- 前天 12:36
- 支持
- 反对
- 回复
- 收藏